- Home
- ABUS vs GHRS Comparison
ABUS vs GHRS Comparison
Compare ABUS & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABUS | GHRS |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.7M | 1.0B |
| IPO Year | 2008 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ABUS | GHRS |
|---|---|---|
| Price | $4.71 | $15.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $5.00 | ★ $40.33 |
| AVG Volume (30 Days) | ★ 2.2M | 165.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.64 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,171,000.00 | N/A |
| Revenue This Year | $125.30 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.71 | $7.98 |
| 52 Week High | $5.10 | $19.51 |
Technical Indicators
Market Signals| Indicator | ABUS | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 58.40 | 52.02 |
| Support Level | $4.18 | $11.84 |
| Resistance Level | $5.01 | $16.22 |
| Average True Range (ATR) | 0.22 | 0.84 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 80.79 | 68.87 |
Price Performance
Historical ComparisonAbout ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.